Search results for "glycopeptide"

showing 10 items of 164 documents

Cover Picture: Synthesis and Biological Evaluation of a Multiantigenic Tn/TF-Containing Glycopeptide Mimic of the Tumor-Related MUC1 Glycoprotein (Ch…

2006

Pharmacologychemistry.chemical_classificationStereochemistryOrganic ChemistryBiochemistryCombinatorial chemistryGlycopeptideSolid-phase synthesischemistryDrug DiscoveryMolecular MedicineCover (algebra)General Pharmacology Toxicology and PharmaceuticsGlycoproteinMUC1Biological evaluationChemMedChem
researchProduct

Phosphate-controlled regulator for the biosynthesis of the dalbavancin precursor A40926

2008

Phosphate-controlled regulatorglycopeptidesSettore BIO/19 - Microbiologia Generaledalbavancin
researchProduct

Differential proteomic analysis highlights metabolic strategies associated with balhimycin production in Amycolatopsis balhimycina chemostat cultivat…

2010

Abstract Background Proteomics was recently used to reveal enzymes whose expression is associated with the production of the glycopeptide antibiotic balhimycin in Amycolatopsis balhimycina batch cultivations. Combining chemostat fermentation technology, where cells proliferate with constant parameters in a highly reproducible steady-state, and differential proteomics, the relationships between physiological status and metabolic pathways during antibiotic producing and non-producing conditions could be highlighted. Results Two minimal defined media, one with low Pi (0.6 mM; LP) and proficient glucose (12 g/l) concentrations and the other one with high Pi (1.8 mM) and limiting (6 g/l; LG) glu…

Proteomemedicine.drug_classlcsh:QR1-502BioengineeringChemostatBiologyGlycopeptide antibioticProteomicsSettore BIO/19 - Microbiologia GeneraleApplied Microbiology and Biotechnologylcsh:Microbiology03 medical and health sciencesBacterial ProteinsVancomycinantibioticActinomycetalesmedicineElectrophoresis Gel Two-DimensionalBalhimycinproteomic030304 developmental biology2. Zero hungerchemistry.chemical_classification0303 health sciences030306 microbiologyResearchFatty AcidsCarbonAnti-Bacterial AgentsMetabolic pathwayglycopeptideEnzymeGlucosechemistryBiochemistryAmycolatopsis balhimycinaProtein BiosynthesisFermentationBiotechnologyMicrobial Cell Factories
researchProduct

Differential proteomic analysis reveals novel links between primary metabolism and antibiotic production in Amycolatopsis balhimycina.

2010

A differential proteomic analysis, based on 2-DE and MS procedures, was performed on Amycolatopsis balhimycina DSM5908, the actinomycete producing the vancomycin-like antibiotic balhimycin. A comparison of proteomic profiles before and during balhimycin production characterized differentially and constitutively expressed protein isoforms, which were associated to 203 ORFs in the A. balhimycina genome. These data, providing insights on the major metabolic pathways/molecular processes operating in this organism, were used to compile 2-DE reference maps covering 3-10, 4-7 and 4.5-5.5 pH gradients available over the World Wide Web as interactive web pages (http://www.unipa.it/ampuglia/Abal-prot…

ProteomicsProteomeAmycolatopsisBiologyProteomicsSettore BIO/19 - Microbiologia GeneraleBiochemistryMass SpectrometryFungal Proteinschemistry.chemical_compoundBiosynthesisVancomycinActinomycetalesProtein biosynthesisCluster AnalysisElectrophoresis Gel Two-Dimensionalglycopeptide antibioticMolecular BiologyGenechemistry.chemical_classificationGene Expression Profiling2-DE reference mapprimary and secondary metabolismMetabolismHydrogen-Ion ConcentrationAmycolatopsis balhimycinabiology.organism_classificationAnti-Bacterial AgentsAmino acidMetabolic pathwaychemistryBiochemistrygene expressionMetabolic Networks and Pathways
researchProduct

Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.

2018

To externally validate the prognostic impact of copeptin, either alone or integrated in risk stratification models, in pulmonary embolism (PE), we performed a post hoc analysis of 843 normotensive PE patients prospectively included in three European cohorts.Within the first 30 days, 21 patients (2.5%, 95% CI 1.5–3.8) had an adverse outcome and 12 (1.4%, 95% CI 0.7–2.5) died due to PE. Patients with copeptin ≥24 pmol·L−1 had a 6.3-fold increased risk for an adverse outcome (95% CI 2.6–15.5, p<0.001) and a 7.6-fold increased risk for PE-related death (95% CI 2.3–25.6, p=0.001). Risk classification according to the 2014 European Society of Cardiology (ESC) guideline algorithm identified 248…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyValidation studyAdverse outcomes030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineCopeptinRisk groupsRisk FactorsInternal medicinePost-hoc analysismedicineHumansProspective StudiesAgedAged 80 and overbusiness.industryGlycopeptidesMiddle Agedmedicine.diseasePrognosisPulmonary embolismIncreased riskLogistic Models030228 respiratory systemROC CurveRisk stratificationFemalebusinessPulmonary EmbolismAlgorithmsBiomarkersThe European respiratory journal
researchProduct

Tumor-Associated MUC1 Tandem-Repeat Glycopeptide Microarrays to Evaluate Serum- and Monoclonal-Antibody Specificity

2009

Repetitive Sequences Amino Acidmedicine.drug_classMolecular Sequence DataMonoclonal antibodyCatalysisMiceTandem repeatAntibody SpecificityNeoplasmsmedicineAnimalsAmino Acid SequencePeptide sequenceMUC1biologyMicroarray analysis techniquesChemistryImmune SeraMucin-1GlycopeptidesAntibodies MonoclonalGeneral MedicineGeneral ChemistryMicroarray AnalysisMolecular biologyGlycopeptideBiochemistrybiology.proteinAntibodyDNA microarrayAngewandte Chemie International Edition
researchProduct

ChemInform Abstract: The Development of Synthetic Antitumor Vaccines from Mucin Glycopeptide Antigens

2013

Solid-phase synthesisBiochemistryAntigenChemistryMucinGeneral MedicineGlycopeptideChemInform
researchProduct

Synthesis of Biologically Interesting Glycopeptides.

1992

哺乳動物に見い出される大部分のタンパクは糖タンパクである。それらの糖鎖は生物学的選択性、特に膜上での認識過程に重要な働きをしている。全ての糖タンパクは糖鎖とペプチドとの間にグリコシド結合を有している。それゆえに糖ペプチドの化学合成は、立体特異的なグリコシド結合の生成と、グリコシド結合に影響を与えない選択的な保護が要求される。ベンジルグループとそれらの水素添加による脱離法は、これらの要求を満たす。しかしながら、これらの保護法を用いる方法は糖質の水酸基のブロックを必要とするので、ペプチド部分の官能基は撰択的に脱離可能でそしてベンジル基に対して orthogonal に安定なグループで保護されなければならない。この意味においてフルオレニルメトキシカルボニル (Fmoc) 基と、弱塩基、モルフォリンによる脱離と、パラジウム (0) 触媒によるアリル基転移によって脱離可能なアリルオキシカルボニル (Aloc) 基は、糖ペプチド化学においてアミノ基の保護基として有用である事が明らかにされた。同様なパラジウム (0) の化学を用いるアリルエステルと、酸により除去可能なtert-ブチルエステルはカルボキシル基の保護に有用である事が分かった。ベンジル基とアリルエステル (HYCRAM™) を用いる糖ペプチドの固相合成におけるアンカーシステムとして有効に利用される事が示された。

Solid-phase synthesisChemistryStereochemistryOrganic ChemistryBiochemistryGlycopeptideTrends in Glycoscience and Glycotechnology
researchProduct

Vom E-Selektin-Liganden 1 abgeleitete Glycopeptide mit variierter Sialyl-Lewisx-Struktur als Zelladhäsionsinhibitoren für E-Selektin

2007

StereochemistryChemistryGeneral MedicineGlycopeptideAngewandte Chemie
researchProduct

ChemInform Abstract: Synthesis of Glycopeptides with Lewisa Antigen Side Chain and HIV Peptide T Sequence Using the Trichloroethoxycarbonyl/Allyl Est…

2010

StereochemistryChemistryHuman immunodeficiency virus (HIV)Peptide TGeneral Medicinemedicine.disease_causeGlycopeptidechemistry.chemical_compoundBiochemistryAntigenmedicineSide chainProtecting groupSequence (medicine)ChemInform
researchProduct